PathAI is a Boston based company building AI tools for pathology, the branch of medicine where doctors dig into tissue samples to figure out what’s actually going wrong inside a patient. The goal was never to replace pathologists, not even close. It’s really about giving them software that runs alongside the work they’re already doing, so labs, drug companies, and clinicians can pull faster, more consistent answers from the exact same slides they’d be reviewing anyway.
You’ve probably noticed the name popping up more lately, and there’s a simple reason for that. Back in May 2026, Roche announced it had agreed to acquire PathAI, a company that’s genuinely earned its reputation in AI powered pathology. The deal would bring PathAI’s digital pathology and AI capabilities into Roche’s Diagnostics division, folding it under the umbrella of one of the largest diagnostics companies on the planet. Here’s a closer look at what PathAI actually does, how the tech underneath it works, what the Roche deal really means, and what working there is like day to day.
What Is PathAI?
PathAI is a healthcare technology company that builds AI software for pathology and digital diagnostics. Founded back in 2016 by Andy Beck and Aditya Khosla, it’s headquartered in Boston, Massachusetts. What makes the company a little unusual is where it actually sits, at the intersection of three worlds that don’t typically overlap: pathology, software engineering, and biopharma research.
PathAI never really set out to become a jack-of-all-trades AI company. From the very beginning, it stuck to one specific lane, analyzing digital images of tissue samples, known as whole-slide images, to pull out measurements, patterns, and quality signals that would take a human considerably longer to spot by eye alone. For a look at how the company describes its own work directly, the official PathAI site lays out its focus across biopharma, labs, and clinicians.
What Does PathAI Do?
Broadly, PathAI’s work breaks down into a handful of areas that all connect back to tissue analysis.
Digital diagnostics. It builds AI models and software that help pathologists review and read tissue slides faster, especially in cancer cases.
Biopharma and clinical trials. Drug companies lean on PathAI’s tools to analyze tissue data at scale during research, which matters a lot in oncology trials where tissue samples are often the main piece of evidence.
Biomarker discovery. The company’s algorithms help researchers notice patterns in tissue images that line up with disease subtypes or how well a patient responds to treatment, which feeds into how new biomarkers get found and validated.
Companion diagnostics. Working with partners like Roche, PathAI has helped build AI-assisted diagnostic tools that support decisions about which patients are likely to benefit from a given drug.
None of this means a computer is quietly making diagnoses on its own. PathAI is pretty clear about this in its own materials: the software is there to support the humans running the workflow, not to override them.
How Does PathAI Work?
Here’s the process in plain terms: a tissue sample goes on a slide, that slide gets scanned into a high-resolution digital image, and the image runs through PathAI’s algorithms. The software can flag anything worth a closer look, measure specific features in the tissue, and help sort cases so a pathologist knows what to look at first.
A pathologist still reviews everything. The AI output is treated as extra information, not a final answer. In practice, the software might help with things like:
- Counting cells or measuring tissue area, which is tedious to do by hand
- Flagging slides that need urgent attention
- Running quality checks on scanned images before a pathologist even opens the case
- Feeding structured data into the reporting process
That’s a different setup than most consumer AI tools you’ve probably used. The output here is built to plug into a regulated clinical or research workflow, not to stand on its own.
What Is PathAI AISight?
AISight, also written as AISight Dx, is PathAI’s main software platform, and AISight is a central part of PathAI’s digital pathology software offering.
It’s a cloud-based digital pathology platform and image management system that lets labs store, view, analyze, and share whole-slide images instead of shipping physical glass slides between offices.
Inside AISight, a lab typically gets:
- One place to manage cases and images
- Case prioritization, so the most urgent slides get seen first
- Automated quality checks on scanned images before diagnosis
- Tools for teams to collaborate on the same case
- AI-assisted measurements layered on top of the images themselves
This matters for the Roche deal because Roche isn’t just picking up an algorithm here. It’s getting a full software layer that labs can plug straight into how they already work, which is a much bigger and longer-lasting asset than one diagnostic model.
What Does a Pathologist Actually Receive From PathAI?
This is one of the more practical questions people search for, so it deserves a straight answer instead of vague marketing talk.
Depending on the specific tool and workflow, a pathologist might get image-based measurements, biomarker scores, tissue classification data, case-priority flags, or quality-control notes on the slide. The exact output depends on the product and its intended use. AI-generated findings are meant to support the applicable pathology workflow, not replace a qualified professional’s interpretation of what’s actually going on with the patient.
PathAI and Roche: What Is the Connection?
2026 wasn’t the start. Roche and PathAI go back further than that. The two started working together in 2021, then took things further in 2024, building AI-enabled companion diagnostic algorithms side by side.
Then, May 7, 2026, Roche pulls the trigger, definitive merger agreement, acquiring PathAI outright. Money breaks down like this: $750 million upfront, another $300 million possible depending on milestones hit down the road. Total potential value, somewhere around $1.05 billion. Deal’s set to close in the second half of 2026, assuming regulatory approvals go through as expected. Once it does, PathAI slots into Roche’s Diagnostics division.
Matt Sause runs Roche Diagnostics as CEO, and he’s framed this whole thing around scaling AISight worldwide, pairing it up with Roche’s existing muscle in oncology companion diagnostics. Outlets like MedTech Dive covered the same numbers, positioning it as part of a bigger shift toward standardized digital pathology across labs everywhere.
One thing worth being precise about, though. As of right now, this hasn’t closed yet. Roche agreed to acquire PathAI, that’s accurate. PathAI being an actual Roche subsidiary already, that’s not, not yet anyway. Small distinction, but it matters if you’re trying to figure out who’s actually calling the shots at PathAI today.
Who Founded PathAI?
PathAI was co-founded by Andy Beck, who has served as CEO since the beginning, along with Aditya Khosla. Beck has remained PathAI’s CEO as the company expanded its AI-powered pathology business and strategic partnerships.
Here’s a quick reference table with the core facts:
| Fact | Details |
|---|---|
| Company | PathAI |
| Founded | 2016 |
| Headquarters | Boston, Massachusetts |
| Industry | AI, digital pathology, healthcare technology |
| Founders | Andy Beck (CEO), Aditya Khosla |
| Core platform | AISight (AISight Dx) |
| Roche connection | Acquisition agreement announced May 7, 2026 |
| Announced deal value | $750M upfront, up to $300M in milestones |
PathAI Careers and Jobs
PathAI hires across a real mix of technical and clinical-adjacent roles, which makes sense given what the company actually builds. Job listings have generally covered software engineering, machine learning and data science, pathology and medical affairs, clinical operations, and business roles supporting biopharma partnerships.
| Career Area | Examples |
|---|---|
| Engineering | Software engineering, platform development |
| AI & Data | Machine learning, data science |
| Pathology | Pathology and medical affairs roles |
| Clinical | Clinical research and operations |
| Business | Commercial and business development |
Locations have included Boston, Memphis, and New York City, plus a good number of remote-friendly roles, especially on the engineering and data side. If you’re considering applying, the current openings are listed on PathAI’s own careers page. It’s worth checking there directly, since roles can shift as the Roche integration moves forward.
PathAI Funding and Growth
PathAI has raised more than $250 million in equity funding over several rounds since its 2016 seed round, with its Series C in 2021 (roughly $165 million) led by D1 Capital Partners and Kaiser Permanente. Other backers over the years have included General Catalyst, General Atlantic, Tiger Global, LabCorp, Merck’s Global Health Innovation Fund, and Bristol Myers Squibb, among others. The company also took on venture debt financing in later years to support its growth. Reported totals vary a bit depending on the source and whether debt financing is included, but the broad picture is a well-capitalized startup with strong backing from both venture investors and strategic healthcare partners, which is part of what made it an attractive acquisition target for Roche.
PathAI’s Role in Digital Pathology
To understand why PathAI matters, it helps to zoom out a bit. Traditional pathology relies on physical glass slides looked at under a microscope, one pathologist at a time, usually in one physical location. Digital pathology moved that process onto scanned images that can be pulled up on a screen and shared electronically. AI-powered digital pathology, which is where PathAI operates, adds a layer of algorithmic analysis on top of those digital images.
This shift isn’t unique to healthcare. A lot of regulated, data-heavy industries have gone through something similar, where AI tools get layered onto digital infrastructure that already exists rather than tearing out the whole process and starting over. In pathology specifically, that means labs can adopt AI assistance gradually, without needing to abandon the systems and workflows they’ve already built around digital slides.
Benefits of PathAI’s AI-Powered Pathology
Faster workflow support. AI-assisted tools can speed up the parts of a pathologist’s day that involve repetitive measurement or slide sorting, freeing up time for the harder judgment calls.
Quantitative tissue analysis. Measurements that used to depend on a pathologist’s eye can now be quantified consistently, which helps with both diagnosis and research.
Support for drug development. Biopharma researchers get a faster way to process large volumes of tissue data during clinical trials, which can shorten parts of the drug development timeline.
Digital collaboration. Because everything lives in a platform like AISight, teams in different locations can review and discuss the same case without shipping physical slides around.
Limitations of AI-Powered Pathology
AI depends on image quality. The algorithms only work as well as the digital images they’re given, so scanning quality and consistency matter a lot.
Algorithms have specific intended uses. A tool built for one type of tissue or one diagnostic task isn’t automatically useful for another. PathAI itself draws a line between products cleared for diagnostic use and tools meant strictly for research.
Regulatory status can differ. What’s approved for clinical use in one market or product line isn’t automatically approved everywhere else.
Professional review still matters. None of this replaces the judgment of a trained pathologist. The output still needs someone qualified to interpret it in context.
Is PathAI Publicly Traded?
No. PathAI is privately held, so there’s no PathAI stock ticker to look up on any exchange. The more relevant story right now is the pending Roche acquisition, since a completed deal would eventually fold PathAI into Roche rather than PathAI ever going public on its own.
Frequently Asked Questions
What is PathAI?
PathAI is a Boston-based company that builds AI software for pathology, helping analyze tissue images for diagnostics, biopharma research, and clinical trials.
What does PathAI do?
It develops AI tools used in digital diagnostics, biomarker discovery, clinical trial support, and companion diagnostics, mainly through its AISight platform.
Who founded PathAI?
PathAI was co-founded by Andy Beck, who serves as CEO, and Aditya Khosla, in 2016.
Is PathAI owned by Roche?
As of September 15, 2026, Roche has announced an agreement to acquire PathAI, but the transaction remains subject to closing conditions. Roche said the acquisition was expected to close in the second half of 2026.
Is PathAI publicly traded?
No. PathAI is privately held and has no public stock listing.
What is PathAI AISight?
PathAI AISight is a digital pathology platform and image management system designed to help laboratories manage, view, analyze, and share digital pathology cases. PathAI’s AISight offering combines image management with workflow and AI-analysis capabilities.
What does PathAI’s diagnostic output actually give a pathologist?
Depending on the tool, outputs can include measurements, biomarker scores, tissue classifications, or quality-control flags. The pathologist still interprets that data within the clinical workflow.
Final Thoughts
PathAI has spent nearly a decade building AI tools meant to work inside existing pathology workflows instead of around them, and its pending acquisition by Roche is a pretty strong sign that approach paid off. Whether you came here to understand what AISight actually does, what a career at PathAI looks like, or what the Roche deal means for digital pathology going forward, this is a company worth keeping an eye on as the acquisition heads toward closing later in 2026. If you’re curious about AI tools more broadly, our AI tools directory has a wider range worth browsing, including several built for industries well outside healthcare.